8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
May 4, 2026·SEC
Material company update
Apr 28, 2026·SEC
Gilead Sciences, Inc.(GILD)Earnings, Financials & Key Ratios
GILD•NASDAQ
18.3× P/E·Price updated Jun 19, 2026
AboutGilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.Show more
- Revenue$29.44B+2.4%
- EBITDA$14.46B+226.5%
- Net Income$8.51B+1672.9%
- EPS (Diluted)6.78+1684.2%
- Gross Margin78.83%+0.7%
- EBITDA Margin49.12%+218.9%
- Operating Margin39.74%+587.6%
- Net Margin28.9%+1631.5%
- ROE40.66%+1678.5%
GILD Key Insights
Gilead Sciences, Inc. (GILD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 22.9%
- ✓Strong 5Y profit CAGR of 133.3%
- ✓Strong Piotroski F-Score: 9/9
- ✓FCF machine: 32.1% free cash flow margin
- ✓11 consecutive years of dividend growth
- ✓Healthy dividend yield of 2.6%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when GILD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GILD Price & Volume
Gilead Sciences, Inc. (GILD) stock price & volume — 10-year historical chart
Loading chart...
GILD Growth Metrics
Gilead Sciences, Inc. (GILD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-1.03%
5 Years3.58%
3 Years2.57%
TTM3.48%
Profit CAGR
10 Years-7.27%
5 Years133.35%
3 Years22.83%
TTM54.5%
EPS CAGR
10 Years-5.48%
5 Years133.63%
3 Years23.04%
TTM54.53%
Return on Capital
10 Years17.03%
5 Years14.82%
3 Years14.35%
Last Year24.84%
GILD Recent Earnings
Gilead Sciences, Inc. (GILD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$2.03+6.3%
$1.91
Rev
$7.0B+0.7%
$6.9B
Q1 2026
Feb 10, 2026Metric
Actual
Est
EPS
$1.86+2.8%
$1.81
Rev
$7.9B+3.1%
$7.7B
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$2.47+16.0%
$2.13
Rev
$7.8B+4.3%
$7.4B
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$2.01+2.6%
$1.96
Rev
$7.1B+1.4%
$7.0B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $2.03vs $1.91+6.3% | $7.0Bvs $6.9B+0.7% |
| Q1 2026 | Feb 10, 2026 | $1.86vs $1.81+2.8% | $7.9Bvs $7.7B+3.1% |
| Q4 2025 | Oct 30, 2025 | $2.47vs $2.13+16.0% | $7.8Bvs $7.4B+4.3% |
| Q3 2025 | Aug 7, 2025 | $2.01vs $1.96+2.6% | $7.1Bvs $7.0B+1.4% |
Based on last 12 quarters of dataView full earnings history →
GILD Peer Comparison
Gilead Sciences, Inc. (GILD) competitors in Specialty and biologics-focused pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 BMY | 110.25B | 54.00 | 15.65 | -0.22% | 15.01% | 38.96% | 2.55 | |
 AMGN | 182.2B | 337.60 | 23.72 | 9.92% | 20.95% | 89.41% | 6.31 | |
 BIIB | 29.02B | 196.58 | 22.26 | 1.39% | 13.92% | 7.55% | 0.38 | |
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 | |
 VRTX | 114.88B | 451.63 | 29.48 | 9.57% | 35.4% | 23.93% | 0.21 | |
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 | |
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 |
Compare GILD vs Peers
Gilead Sciences, Inc. (GILD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GILD Income Statement
Gilead Sciences, Inc. (GILD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 26.11B | 22.13B | 22.45B | 24.69B | 27.3B | 27.28B | 27.12B | 28.75B | 29.44B | 29.73B |
Revenue Growth % | -14.09% | -15.25% | 1.46% | 9.98% | 10.6% | -0.09% | -0.6% | 6.04% | 2.39% | 3.48% |
Cost of Goods Sold | 4.37B | 4.85B | 4.67B | 4.57B | 6.6B | 5.66B | 6.5B | 6.25B | 6.23B | 6.14B |
COGS % of Revenue | 16.74% | 21.93% | 20.82% | 18.52% | 24.18% | 20.74% | 23.96% | 21.74% | 21.17% | - |
Gross Profit | 21.74B▲ 0% | 17.27B▼ 20.5% | 17.77B▲ 2.9% | 20.12B▲ 13.2% | 20.7B▲ 2.9% | 21.62B▲ 4.4% | 20.62B▼ 4.7% | 22.5B▲ 9.1% | 23.21B▲ 3.1% | 23.59B▲ 0% |
Gross Margin % | 83.26% | 78.07% | 79.17% | 81.48% | 75.82% | 79.26% | 76.04% | 78.26% | 78.83% | 79.35% |
Gross Profit Growth % | -16.81% | -20.53% | 2.89% | 13.18% | 2.92% | 4.44% | -4.65% | 9.14% | 3.13% | - |
Operating Expenses | 7.61B | 7.98B | 8.44B | 16.05B | 10.79B | 14.29B | 13.01B | 20.84B | 11.51B | 12.22B |
OpEx % of Revenue | 29.16% | 36.05% | 37.58% | 64.99% | 39.5% | 52.4% | 47.99% | 72.48% | 39.08% | - |
Selling, General & Admin | 3.88B | 4.06B | 4.38B | 5.11B | 5.25B | 5.67B | 6.09B | 6.09B | 5.71B | 5.9B |
SG&A % of Revenue | 14.85% | 18.33% | 19.52% | 20.71% | 19.21% | 20.79% | 22.46% | 21.18% | 19.39% | - |
Research & Development | 3.73B | 3.92B | 4.05B | 5.04B | 4.6B | 4.98B | 5.72B | 5.91B | 5.8B | 5.79B |
R&D % of Revenue | 14.3% | 17.72% | 18.06% | 20.41% | 16.85% | 18.24% | 21.09% | 20.54% | 19.7% | - |
Other Operating Expenses | 0 | 0 | 0 | 5.89B | 939M | 3.64B | 1.21B | 8.84B | 0 | 3M |
Operating Income | 14.12B▲ 0% | 8.2B▼ 41.9% | 4.29B▼ 47.7% | 4.07B▼ 5.0% | 9.92B▲ 143.6% | 7.33B▼ 26.1% | 7.61B▲ 3.8% | 1.66B▼ 78.1% | 11.7B▲ 604.0% | 11.38B▲ 0% |
Operating Margin % | 54.1% | 37.06% | 19.1% | 16.49% | 36.32% | 26.87% | 28.05% | 5.78% | 39.74% | 38.26% |
Operating Income Growth % | -19.9% | -41.94% | -47.72% | -5.04% | 143.63% | -26.09% | 3.75% | -78.15% | 604.03% | - |
EBITDA | 15.41B | 9.63B | 5.69B | 5.55B | 11.97B | 9.43B | 10.3B | 4.43B | 14.46B | 13.2B |
EBITDA Margin % | 59.03% | 43.52% | 25.35% | 22.48% | 43.83% | 34.58% | 37.98% | 15.4% | 49.12% | 44.41% |
EBITDA Growth % | -17.99% | -37.51% | -40.9% | -2.46% | 115.6% | -21.18% | 9.17% | -56.99% | 226.51% | 20.1% |
D&A (Non-Cash Add-back) | 1.29B | 1.43B | 1.4B | 1.48B | 2.05B | 2.1B | 2.69B | 2.77B | 2.76B | 2.06B |
EBIT | 14.65B | 8.88B | 6.16B | 2.65B | 9.28B | 6.75B | 7.8B | 1.67B | 10.82B | 11.26B |
Net Interest Income | -1.12B | -1.08B | -995M | -984M | -1B | -829M | -568M | -696M | -675M | -749M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 106M | 376M | 281M | 349M | 256M |
Interest Expense | 1.12B | 1.08B | 995M | 984M | 1B | 935M | 944M | 977M | 1.02B | 1B |
Other Income/Expense | -595M | -401M | 873M | -2.4B | -1.64B | -1.52B | -746M | -972M | -1.91B | -647M |
Pretax Income | 13.53B▲ 0% | 7.8B▼ 42.4% | 5.16B▼ 33.8% | 1.67B▼ 67.7% | 8.28B▲ 396.0% | 5.81B▼ 29.8% | 6.86B▲ 18.0% | 690M▼ 89.9% | 9.8B▲ 1319.7% | 10.73B▲ 0% |
Pretax Margin % | 51.82% | 35.25% | 22.99% | 6.76% | 30.32% | 21.31% | 25.3% | 2.4% | 33.27% | 36.08% |
Income Tax | 8.88B | 2.34B | -204M | 1.58B | 2.08B | 1.25B | 1.25B | 211M | 1.29B | 1.51B |
Effective Tax Rate % | 65.67% | 29.99% | -3.95% | 94.67% | 25.09% | 21.47% | 18.18% | 30.58% | 13.13% | 14.08% |
Net Income | 4.63B▲ 0% | 5.46B▲ 17.9% | 5.39B▼ 1.3% | 123M▼ 97.7% | 6.22B▲ 4961.0% | 4.59B▼ 26.2% | 5.67B▲ 23.4% | 480M▼ 91.5% | 8.51B▲ 1672.9% | 9.22B▲ 0% |
Net Margin % | 17.73% | 24.65% | 23.99% | 0.5% | 22.8% | 16.83% | 20.89% | 1.67% | 28.9% | 30.99% |
Net Income Growth % | -65.72% | 17.87% | -1.26% | -97.72% | 4960.98% | -26.23% | 23.37% | -91.53% | 1672.92% | 54.5% |
Net Income (Continuing) | 4.64B | 5.46B | 5.36B | 89M | 6.2B | 4.57B | 5.61B | 479M | 8.51B | 9.22B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 59M | 147M | 125M | 19M | -5M | -31M | -84M | -84M | 0 | -84M |
EPS (Diluted) | 3.51▲ 0% | 4.17▲ 18.8% | 4.22▲ 1.2% | 0.10▼ 97.7% | 4.93▲ 4961.6% | 3.64▼ 26.2% | 4.50▲ 23.6% | 0.38▼ 91.6% | 6.78▲ 1684.2% | 7.35▲ 0% |
EPS Growth % | -64.69% | 18.8% | 1.2% | -97.69% | 4961.6% | -26.17% | 23.63% | -91.56% | 1684.21% | 54.53% |
EPS (Basic) | 3.54 | 4.20 | 4.24 | 0.10 | 4.96 | 3.66 | 4.54 | 0.38 | 6.84 | - |
Diluted Shares Outstanding | 1.32B | 1.31B | 1.28B | 1.26B | 1.26B | 1.26B | 1.26B | 1.25B | 1.25B | 1.25B |
Basic Shares Outstanding | 1.31B | 1.3B | 1.27B | 1.26B | 1.26B | 1.25B | 1.25B | 1.25B | 1.24B | 1.24B |
Dividend Payout Ratio | 59.01% | 54.46% | 59.82% | 2804.07% | 57.91% | 80.77% | 67.24% | 816.25% | 47.04% | - |
GILD Balance Sheet
Gilead Sciences, Inc. (GILD) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 31.82B | 35.84B | 30.3B | 16B | 14.77B | 14.44B | 16.09B | 19.17B | 19.89B | 18.64B |
Cash & Short-Term Investments | 25.51B | 30.09B | 24.35B | 7.41B | 6.52B | 6.38B | 7.26B | 11.57B | 10.61B | 9.82B |
Cash Only | 7.59B | 17.94B | 11.63B | 6B | 5.34B | 5.41B | 6.08B | 9.99B | 7.56B | 7.63B |
Short-Term Investments | 17.92B | 12.15B | 12.72B | 1.41B | 1.18B | 973M | 1.18B | 1.58B | 3.04B | 2.19B |
Accounts Receivable | 3.85B | 3.33B | 3.58B | 4.89B | 4.49B | 4.78B | 4.66B | 4.42B | 4.91B | 4.74B |
Days Sales Outstanding | 53.84 | 54.88 | 58.24 | 72.32 | 60.06 | 63.91 | 62.73 | 56.11 | 60.91 | 59.94 |
Inventory | 801M | 814M | 922M | 1.68B | 1.62B | 1.51B | 1.79B | 1.71B | 4.37B | 1.91B |
Days Inventory Outstanding | 66.89 | 61.22 | 71.98 | 134.36 | 89.47 | 97.23 | 100.38 | 99.85 | 255.75 | 147.03 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 2.37B | 995M | 0 | 2.17B |
Total Non-Current Assets | 38.46B | 27.84B | 31.33B | 52.41B | 53.18B | 48.73B | 46.04B | 39.82B | 39.14B | 37.64B |
Property, Plant & Equipment | 3.29B | 4.01B | 4.5B | 4.97B | 5.12B | 5.47B | 5.32B | 5.41B | 5.61B | 5.64B |
Fixed Asset Turnover | 7.92x | 5.52x | 4.99x | 4.97x | 5.33x | 4.98x | 5.10x | 5.31x | 5.25x | 5.36x |
Goodwill | 4.16B | 4.12B | 4.12B | 8.11B | 8.33B | 8.31B | 8.31B | 8.31B | 8.31B | 8.31B |
Intangible Assets | 17.1B | 15.74B | 13.79B | 33.13B | 33.45B | 28.89B | 26.45B | 19.95B | 16.98B | 16.38B |
Long-Term Investments | 11.18B | 1.42B | 1.49B | 502M | 1.31B | 1.25B | 1.16B | 0 | 0 | 5.59B |
Other Non-Current Assets | 2.72B | 2.56B | 7.44B | 5.71B | 4.96B | 4.8B | 4.79B | 6.15B | 8.24B | 3.86B |
Total Assets | 70.28B▲ 0% | 63.67B▼ 9.4% | 61.63B▼ 3.2% | 68.41B▲ 11.0% | 67.95B▼ 0.7% | 63.17B▼ 7.0% | 62.13B▼ 1.7% | 58.99B▼ 5.0% | 59.02B▲ 0.0% | 56.28B▲ 0% |
Asset Turnover | 0.37x | 0.35x | 0.36x | 0.36x | 0.40x | 0.43x | 0.44x | 0.49x | 0.50x | 0.52x |
Asset Growth % | 23.35% | -9.4% | -3.22% | 11% | -0.67% | -7.04% | -1.66% | -5.04% | 0.05% | 11.12% |
Total Current Liabilities | 11.63B | 10.61B | 9.76B | 11.4B | 11.61B | 11.24B | 11.28B | 12B | 11.81B | 9.48B |
Accounts Payable | 814M | 790M | 713M | 844M | 705M | 905M | 550M | 833M | 0 | 645M |
Days Payables Outstanding | 67.97 | 59.42 | 55.67 | 67.38 | 38.98 | 58.39 | 30.89 | 48.64 | - | 30.25 |
Short-Term Debt | 2.75B | 2.75B | 2.5B | 2.76B | 1.52B | 2.27B | 1.8B | 1.81B | 0 | 1.31B |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 455M | 555M | 736M | 1.45B | 1.43B | 3.62B | 3.92B | 3.82B | 11.81B | 7.52B |
Current Ratio | 2.74x | 3.38x | 3.10x | 1.40x | 1.27x | 1.29x | 1.43x | 1.60x | 1.68x | 1.97x |
Quick Ratio | 2.67x | 3.30x | 3.01x | 1.26x | 1.13x | 1.15x | 1.27x | 1.45x | 1.31x | 1.77x |
Cash Conversion Cycle | 52.76 | 56.69 | 74.56 | 139.3 | 110.54 | 102.75 | 132.21 | 107.32 | - | 176.72 |
Total Non-Current Liabilities | 38.15B | 31.54B | 29.22B | 38.79B | 35.28B | 30.72B | 28.1B | 27.75B | 24.59B | 23.37B |
Long-Term Debt | 30.8B | 24.57B | 22.09B | 28.64B | 25.18B | 22.96B | 23.19B | 24.9B | 24.59B | 20.86B |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 3.91B | 4.36B | 2.67B | 1.59B | 724M | 0 | 1.64B |
Other Non-Current Liabilities | 7.35B | 6.96B | 7.12B | 6.23B | 5.74B | 5.09B | 3.32B | 2.13B | 0 | 2.12B |
Total Liabilities | 49.78B | 42.14B | 38.98B | 50.19B | 46.89B | 41.96B | 39.38B | 39.75B | 36.41B | 32.85B |
Total Debt | 33.54B | 27.32B | 24.59B | 31.4B | 26.7B | 25.23B | 24.99B | 26.71B | 24.59B | 22.17B |
Net Debt | 25.95B | 9.38B | 12.96B | 25.41B | 21.36B | 19.82B | 18.9B | 16.72B | 17.03B | 14.55B |
Debt / Equity | 1.64x | 1.27x | 1.09x | 1.72x | 1.27x | 1.19x | 1.10x | 1.39x | 1.09x | 0.95x |
Debt / EBITDA | 2.18x | 2.84x | 4.32x | 5.66x | 2.23x | 2.67x | 2.43x | 6.03x | 1.70x | 1.68x |
Net Debt / EBITDA | 1.68x | 0.97x | 2.28x | 4.58x | 1.78x | 2.10x | 1.84x | 3.78x | 1.18x | 1.10x |
Interest Coverage | 13.10x | 8.24x | 6.19x | 2.70x | 9.27x | 7.22x | 8.27x | 1.71x | 10.57x | 11.21x |
Total Equity | 20.5B▲ 0% | 21.53B▲ 5.0% | 22.65B▲ 5.2% | 18.22B▼ 19.6% | 21.06B▲ 15.6% | 21.21B▲ 0.7% | 22.75B▲ 7.3% | 19.25B▼ 15.4% | 22.62B▲ 17.5% | 23.43B▲ 0% |
Equity Growth % | 5.88% | 5.04% | 5.18% | -19.55% | 15.6% | 0.69% | 7.26% | -15.4% | 17.52% | 64.67% |
Book Value per Share | 15.54 | 16.46 | 17.74 | 14.43 | 16.69 | 16.81 | 18.08 | 15.34 | 18.02 | 18.69 |
Total Shareholders' Equity | 20.44B | 21.39B | 22.52B | 18.2B | 21.07B | 21.24B | 22.83B | 19.33B | 22.62B | 23.52B |
Common Stock | 1M | 1M | 1M | 1M | 1M | 1M | 1M | 1M | 22.62B | 1M |
Retained Earnings | 19.01B | 19.02B | 19.39B | 14.38B | 16.32B | 15.69B | 16.3B | 11.5B | 0 | 14.13B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 165M | 80M | 85M | -60M | 83M | 2M | 28M | 132M | 0 | 78M |
Minority Interest | 59M | 147M | 125M | 19M | -5M | -31M | -84M | -84M | 0 | -84M |
GILD Cash Flow Statement
Gilead Sciences, Inc. (GILD) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 11.9B | 8.4B | 9.14B | 8.17B | 11.38B | 9.07B | 8.01B | 10.83B | 10.02B | 10.81B |
Operating CF Margin % | 45.57% | 37.96% | 40.73% | 33.08% | 41.69% | 33.25% | 29.53% | 37.66% | 34.03% | - |
Operating CF Growth % | -30.2% | -29.4% | 8.86% | -10.67% | 39.37% | -20.31% | -11.75% | 35.25% | -7.47% | 14.37% |
Net Income | 4.64B | 5.46B | 5.36B | 123M | 6.2B | 4.59B | 5.67B | 480M | 8.51B | 9.22B |
Depreciation & Amortization | 1.29B | 1.43B | 1.4B | 1.48B | 2.05B | 2.1B | 2.69B | 2.77B | 2.76B | 2.73B |
Stock-Based Compensation | 638M | 845M | 636M | 643M | 635M | 644M | 766M | 835M | 0 | 455M |
Deferred Taxes | -82M | 289M | -2.1B | -214M | -116M | -1.55B | -962M | -1.84B | 160M | 538M |
Other Non-Cash Items | 304M | 1.32B | 4.64B | 7.77B | 2.13B | 5.05B | 2.15B | 9.47B | 2.54B | 1.49B |
Working Capital Changes | 5.11B | -939M | -798M | -1.64B | 489M | -1.76B | -2.3B | -880M | -3.95B | -3.63B |
Change in Receivables | 754M | 480M | -218M | -1.17B | 313M | -406M | 157M | 139M | -367M | -312M |
Change in Inventory | -253M | -310M | -95M | -195M | 11M | -310M | -842M | -426M | -1.04B | -865M |
Change in Payables | -430M | -39M | -61M | 80M | -118M | 226M | -347M | 290M | -132M | -94M |
Cash from Investing | -16.07B | 14.36B | -7.82B | -14.62B | -3.13B | -2.47B | -2.27B | -3.45B | -4.79B | -2.61B |
Capital Expenditures | -590M | -924M | -825M | -650M | -579M | -728M | -585M | -523M | -563M | -576M |
CapEx % of Revenue | 2.26% | 4.18% | 3.67% | 2.63% | 2.12% | 2.67% | 2.16% | 1.82% | 1.91% | 1.94% |
Acquisitions | -10.43B | 0 | -4.25B | -25.74B | -1.58B | -1.8B | -1.15B | -4.84B | -1.07B | -906M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -190M | -434M | -171M | 19M | -1M | 0 | 58M | 3M | 9M |
Cash from Financing | 3.39B | -12.32B | -7.63B | 770M | -8.88B | -6.47B | -5.13B | -3.43B | -7.75B | -8.56B |
Debt Issued (Net) | 7.17B | -6.25B | -2.75B | 5.68B | -4.75B | -1.5B | -270M | 1.49B | -1.79B | -2.79B |
Equity Issued (Net) | -720M | -2.61B | -1.54B | -1.33B | -377M | -1.09B | -768M | -728M | -1.51B | -1.29B |
Dividends Paid | -2.73B | -2.97B | -3.22B | -3.45B | -3.6B | -3.71B | -3.81B | -3.92B | -4B | -4.03B |
Share Repurchases | -954M | -2.9B | -1.75B | -1.58B | -546M | -1.4B | -1B | -1.15B | -1.92B | -1.61B |
Other Financing | -330M | -486M | -122M | -138M | -145M | -173M | -278M | -281M | -440M | -444M |
Net Change in Cash | -641M▲ 0% | 10.35B▲ 1715.0% | -6.31B▼ 160.9% | -5.63B▲ 10.7% | -659M▲ 88.3% | 74M▲ 111.2% | 673M▲ 809.5% | 3.91B▲ 480.4% | -2.43B▼ 162.1% | -298M▲ 0% |
Free Cash Flow | 11.31B▲ 0% | 7.48B▼ 33.9% | 8.32B▲ 11.3% | 7.52B▼ 9.6% | 10.8B▲ 43.7% | 8.34B▼ 22.8% | 7.42B▼ 11.1% | 10.3B▲ 38.9% | 9.46B▼ 8.2% | 10.23B▲ 0% |
FCF Margin % | 43.31% | 33.79% | 37.06% | 30.45% | 39.57% | 30.59% | 27.37% | 35.84% | 32.12% | 34.4% |
FCF Growth % | -30.62% | -33.89% | 11.28% | -9.63% | 43.72% | -22.78% | -11.06% | 38.86% | -8.24% | 3.91% |
FCF per Share | 8.57 | 5.72 | 6.51 | 5.95 | 8.56 | 6.61 | 5.90 | 8.21 | 7.53 | 8.16 |
FCF Conversion (FCF/Net Income) | 2.57x | 1.54x | 1.70x | 66.41x | 1.83x | 1.98x | 1.41x | 22.56x | 1.18x | 1.11x |
Interest Paid | 1.04B | 1.07B | 982M | 951M | 979M | 907M | 891M | 951M | 0 | 0 |
Taxes Paid | 3.34B | 3.2B | 1.79B | 2.64B | 2.51B | 3.14B | 3.99B | 2.78B | 0 | 0 |
GILD Key Ratios
Gilead Sciences, Inc. (GILD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 23.22% | 25.95% | 24.38% | 0.6% | 31.69% | 21.73% | 25.77% | 2.29% | 40.66% | 42.33% |
Return on Invested Capital (ROIC) | 25.24% | 15.9% | 9.67% | 7.71% | 17.29% | 13.18% | 13.8% | 3.21% | 23.21% | 21.86% |
Gross Margin | 83.26% | 78.07% | 79.17% | 81.48% | 75.82% | 79.26% | 76.04% | 78.26% | 78.83% | 79.35% |
Net Margin | 17.73% | 24.65% | 23.99% | 0.5% | 22.8% | 16.83% | 20.89% | 1.67% | 28.9% | 30.99% |
Debt / Equity | 1.64x | 1.27x | 1.09x | 1.72x | 1.27x | 1.19x | 1.10x | 1.39x | 1.09x | 0.95x |
Interest Coverage | 13.10x | 8.24x | 6.19x | 2.70x | 9.27x | 7.22x | 8.27x | 1.71x | 10.57x | 11.21x |
FCF Conversion | 2.57x | 1.54x | 1.70x | 66.41x | 1.83x | 1.98x | 1.41x | 22.56x | 1.18x | 1.11x |
Revenue Growth | -14.09% | -15.25% | 1.46% | 9.98% | 10.6% | -0.09% | -0.6% | 6.04% | 2.39% | 3.48% |
Related:GILD Dividend History·GILD Revenue History·GILD Price History·GILD P/E History·GILD Financial Ratios·GILD Institutional Holders
GILD SEC Filings & Documents
Gilead Sciences, Inc. (GILD) SEC filings — annual & quarterly reports (10-K, 10-Q)
GILD Frequently Asked Questions
Gilead Sciences, Inc. (GILD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Gilead Sciences, Inc. (GILD) reported $29.73B in revenue for fiscal year 2025. This represents a 88924% increase from $33.4M in 1996.
Gilead Sciences, Inc. (GILD) grew revenue by 2.4% over the past year. Growth has been modest.
Yes, Gilead Sciences, Inc. (GILD) is profitable, generating $9.22B in net income for fiscal year 2025 (28.9% net margin).
Dividend & Returns
Yes, Gilead Sciences, Inc. (GILD) pays a dividend with a yield of 2.58%. This makes it attractive for income-focused investors.
Gilead Sciences, Inc. (GILD) has a return on equity (ROE) of 40.7%. This is excellent, indicating efficient use of shareholder capital.
Gilead Sciences, Inc. (GILD) generated $10.23B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.